Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram
Important Resources for the MS community are found on the left side of this blog.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, February 9, 2013
Treating Multiple Sclerosis with Skin
Thursday, February 7, 2013
Published: February 6, 2013
DUBLIN (Reuters) — The Irish drug maker Elan will raise more than $3.25 billion by selling its interests in its main drug to its partner, Biogen Idec, and will try to reinvent itself by using most of the cash on acquisitions.
Under a deal announced on Wednesday, Biogen Idec will take full ownership of the blockbuster multiple sclerosis treatment Tysabri and will make an upfront payment to Elan plus royalties on future sales.
While the deal gives Elan scope to return some cash to shareholders as well as strategic flexibility to buy new assets, it leaves its future shape unclear. Tysabri was by far its most important product, responsible for almost all of its revenue.
Elan has already spoken to several companies about potential deals and can move quickly over the next 12 to 18 months once the sale is completed, Kelly Martin, the chief executive of Elan, said in an interview.
“You can do a lot of things with $3 billion — you can buy companies, molecules, you can partner, you can share risk. The world is our oyster,” Mr. Martin said.
“We are not necessarily restricting ourselves to one therapeutic area or one type of clinical asset. We will not be restricted to our past, which was by and large neurological.”
Mr. Martin said there were hundreds of small- to medium-size drug companies with capital or capability needs, meaning there were an “enormous amount of transactions” Elan could do.
Wednesday, February 6, 2013
With more and more people interested in unconventional therapies instead of generic drugs, there is an increasing number of natural treatments for an abundance of conditions
Natural Multiple Sclerosis Treatment System and Directed Nutrition Diet Revealed by SclerosisTreatment.com
With more and more people interested in unconventional therapies instead of generic drugs, there is an increasing number of natural treatments for a plethora of conditions. According to Ironclad Integrity Ltd http://www.SclerosisTreatment.com promotes only natural treatments, herbal therapy, Directed Nutrition as healthy methods to reduce the effect of symptoms and deliver a cure in the long run.
Request your Rebif Information Kit
.. CLICK HERE to Provide your information to REBIF.com
Sunday, February 3, 2013